<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965311</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00022619</org_study_id>
    <secondary_id>NCI-2021-06239</secondary_id>
    <secondary_id>STUDY00022619</secondary_id>
    <nct_id>NCT04965311</nct_id>
  </id_info>
  <brief_title>Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy</brief_title>
  <official_title>A Phase II Trial of Pre-Operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the effect of botulinum toxin (Botox) in preventing postoperative&#xD;
      pancreatic fistula after distal pancreatectomy. Postoperative pancreatic fistula (POPF) is a&#xD;
      known risk of distal pancreatic surgery, in which leakage of pancreatic digestive liquids&#xD;
      causes internal swelling that can be painful (termed inflammation). A valve-like muscle,&#xD;
      called the Sphincter of Oddi, opens and closes, controlling the flow of digestive liquids&#xD;
      from the liver (bile) and pancreas (pancreatic juice) to the small intestine (duodenum).&#xD;
      After surgery, the Sphincter of Oddi may act to block the flow of normal pancreatic&#xD;
      secretions, causing secretions to leak into the abdomen resulting in POPF. Botox is a drug&#xD;
      that can cause paralysis of muscles. Giving an injection of Botox into the sphincter of Oddi&#xD;
      before distal pancreatic surgery may reduce leakage of digestive fluids and potential POPF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate the efficacy of pre-operative botulinum toxin type A (BTX) injection compared to&#xD;
      no therapy for the prevention of clinically relevant POPF at 30 days postoperatively.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the safety of pre-operative BTX injection into the Sphincter of Oddi.&#xD;
&#xD;
      II. Evaluate the efficacy of pre-operative BTX injection compared to no therapy for the&#xD;
      prevention of all POPF at 30 days postoperatively.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive botulinum toxin type A via endoscopic injection into intraduodenal sphincter&#xD;
      of Oddi segment between 7-14 days prior to planned distal pancreas resection.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for up to 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clinically relevant postoperative pancreatic fistula (POPF)</measure>
    <time_frame>Up to postoperative day 30</time_frame>
    <description>Defined by standard biochemical definitions of POPF per the International Study Group of Pancreatic Fistula (ISGPF) criteria. will be measured and reported with 95% exact confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of serious adverse event</measure>
    <time_frame>Up to 30 days following study intervention</time_frame>
    <description>Using the safety analysis set, the incidence of serious adverse events following endoscopic BTX injection into the sphincter of Oddi as a single agent will be determined for participants undergoing distal pancreas resections. The 95% confidence interval will be reported with the point estimate of serious adverse events (SAE) rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any POPF</measure>
    <time_frame>Up to postoperative day 30</time_frame>
    <description>Will be measured and reported with 95% exact confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment of POPF (botulinum toxin type A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive botulinum toxin type A via endoscopic injection into intraduodenal sphincter of Oddi segment between 7-14 days prior to planned distal pancreas resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Given via endoscopic injection into intraduodenal sphincter of Oddi segment</description>
    <arm_group_label>Treatment of POPF (botulinum toxin type A)</arm_group_label>
    <other_name>AbobotulinumtoxinA</other_name>
    <other_name>Botox</other_name>
    <other_name>Botox Cosmetic</other_name>
    <other_name>Botulinum A Toxin</other_name>
    <other_name>Botulinum Neurotoxin Type A</other_name>
    <other_name>Botulinum Toxin A</other_name>
    <other_name>BTX-A</other_name>
    <other_name>DaxibotulinumtoxinA</other_name>
    <other_name>Dysport</other_name>
    <other_name>EvabotulinumtoxinA</other_name>
    <other_name>IncobotulinumtoxinA</other_name>
    <other_name>OnabotulinumtoxinA</other_name>
    <other_name>Onaclostox</other_name>
    <other_name>Prabotulinumtoxin A</other_name>
    <other_name>Xeomin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant scheduled for elective distal pancreatectomy or radical antegrade modular&#xD;
             pancreatosplenectomy (RAMPS), via open or laparoscopic technique&#xD;
&#xD;
          -  Participant &gt;= 18 years of age&#xD;
&#xD;
          -  Ability to understand nature and individual consequences of clinical trial&#xD;
&#xD;
          -  Written informed consent from participant or legally authorized representative&#xD;
&#xD;
          -  For participants of childbearing potential, a negative pregnancy test and adequate&#xD;
             contraception until 14 days after trial intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any BTX preparation or to any of the components in the&#xD;
             formulation&#xD;
&#xD;
          -  Infection at the proposed injection site, including cholangitis&#xD;
&#xD;
          -  Anatomy incompatible with planned intervention (e.g., Roux-en-Y gastric bypass, distal&#xD;
             gastrectomy with Roux-en-Y or Billroth II reconstruction)&#xD;
&#xD;
          -  Acute pancreatitis within 2 weeks of planned study intervention&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) score &gt; III&#xD;
&#xD;
          -  Serious cardiovascular disease (e.g., myocardial infarction in the past year, New York&#xD;
             Heart Association [NYHA] III/IV congestive heart failure, unstable angina)&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          -  Liver cirrhosis (of any Child-Pugh grade)&#xD;
&#xD;
          -  Neuromuscular or any neurological disease with associated increased risk for a&#xD;
             participant undergoing BTX injection&#xD;
&#xD;
          -  Prior BTX administration with either positive or absent testing for neutralizing&#xD;
             antibodies to BTX&#xD;
&#xD;
          -  Inability to obtain informed consent due to comprehension or language barrier&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Any condition that could result in undue risk for the participant and/or influence&#xD;
             outcome measures (in the opinion of the investigator)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett C Sheppard, M.D., FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brett C. Sheppard, M.D., FACS</last_name>
      <phone>503-494-1502</phone>
      <email>sheppard@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Brett C. Sheppard, M.D., FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Brett C. Sheppard, M.D., FACS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatic Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

